BioCentury | Feb 13, 2021
Finance

Qiming readies to kick off Chinese New Year with a first for Hong Kong exchange

...including Zai Lab Ltd. (NASDAQ:ZLAB; HKEX:9688) and dMed...
BioCentury | Dec 18, 2020
Deals

Dec. 17 Quick Takes: Ultragenyx gains rights to Mereo’s setrusumab; plus Verily’s $700M raise, dMed’s listing plans, Virios’ IPO

...chronic disease management. Some money is earmarked for life sciences programs in surgery, pathology and immunology.dMed...
...via $100M roundFidelity Management & Research Co. led a $100 million series C round in dMed...
...$10. The company closed up $6.71 (67%) to $16.71 on the day. BC Staff Setrusumab (BPS804, BPS-804) Ultragenyx Mereo BioPharma Verily dMed...
BioCentury | Sep 10, 2020
Product Development

Qiming’s Leung: COVID-19 response displays the deep networks of China’s biotech ecosystem: a BioCentury audio interview

...having been an early investor entitlement in dMed...
BioCentury | Jun 20, 2020
Product Development

中国为具有前瞻性思维的生物科技公司提供了不仅仅是临床试验重回正轨的机遇

...如此快速的变化和重新评估几乎是不可能的。但在疫情下,它们的确是必需的。谭凌实是缔脉生物医药科技有限公司的创始人,董事长兼首席执行官。嘉宾评论观点不一定代表BioCentury的立场。 谭凌实,缔脉生物医药科技有限公司 dMed...
BioCentury | Jun 20, 2020
Product Development

China offers forward-thinking biotechs much more than an opportunity to get delayed clinical trials back on track

...the pandemic today can be built into a long-term China strategy for tomorrow.” Lingshi Tan, dMed...
...CEO at dMed. Signed commentaries do not necessarily reflect the views of BioCentury. Lingshi Tan, dMed Global dMed...
BioCentury | Feb 8, 2020
Product Development

As coronavirus disrupts MNC operations in China, companies look to digital solutions

...stopped in most hospitals,” said Yan Yi, head of clinical and commercial operations at CRO dMed...
...such as prioritizing the most urgent trials to address current disruptions. Digital solutions Zhang and dMed's...
...are in better shape to manage the current situation.” George Baeder, dMed According to Baeder, dMed...
BioCentury | Nov 18, 2019
Finance

How Quan intends to build cross-border start-ups with second fund

...fund invested in 11 companies and has exited two of them, Armo BioSciences Inc and dMed...
...and Co. (NYSE:LLY) acquired Armo last year for $1.6 billion last year. Quan invested in dMed...
BioCentury | Nov 18, 2019
Finance

How Quan intends to build cross-border start-ups with its second fund

...fund invested in 11 companies and has exited two of them, Armo BioSciences Inc and dMed...
...and Co. (NYSE:LLY) acquired Armo last year for $1.6 billion last year. Quan invested in dMed...
BioCentury | Oct 17, 2019
Financial News

Oct. 16 Financial Quick Takes: Hong Kong IPO could value Ascentage at $876M; plus Principia, Rhythm, ProQR, dMed, Ionova and Amarna

...a 12% discount from Tuesday’s close of $6.22. Vivo leads dMed's $50M series B Shanghai-based dMed...
...will allow the CRO to expand its clinical operations and information technology infrastructure. In June, dMed...
...appointed Thomas Eldered as chair. Hongjiang Li, Staff Writer and Val Kennedy, Associate Editor Ascentage Pharma Group International dMed...
BioCentury | Sep 26, 2019
Tools & Techniques

Biotechs propose solutions to impending shortage of AI talent

...looking to fill a different talent gap: the need for clinical trial specialists in China. dMed...
Items per page:
1 - 10 of 32
BioCentury | Feb 13, 2021
Finance

Qiming readies to kick off Chinese New Year with a first for Hong Kong exchange

...including Zai Lab Ltd. (NASDAQ:ZLAB; HKEX:9688) and dMed...
BioCentury | Dec 18, 2020
Deals

Dec. 17 Quick Takes: Ultragenyx gains rights to Mereo’s setrusumab; plus Verily’s $700M raise, dMed’s listing plans, Virios’ IPO

...chronic disease management. Some money is earmarked for life sciences programs in surgery, pathology and immunology.dMed...
...via $100M roundFidelity Management & Research Co. led a $100 million series C round in dMed...
...$10. The company closed up $6.71 (67%) to $16.71 on the day. BC Staff Setrusumab (BPS804, BPS-804) Ultragenyx Mereo BioPharma Verily dMed...
BioCentury | Sep 10, 2020
Product Development

Qiming’s Leung: COVID-19 response displays the deep networks of China’s biotech ecosystem: a BioCentury audio interview

...having been an early investor entitlement in dMed...
BioCentury | Jun 20, 2020
Product Development

中国为具有前瞻性思维的生物科技公司提供了不仅仅是临床试验重回正轨的机遇

...如此快速的变化和重新评估几乎是不可能的。但在疫情下,它们的确是必需的。谭凌实是缔脉生物医药科技有限公司的创始人,董事长兼首席执行官。嘉宾评论观点不一定代表BioCentury的立场。 谭凌实,缔脉生物医药科技有限公司 dMed...
BioCentury | Jun 20, 2020
Product Development

China offers forward-thinking biotechs much more than an opportunity to get delayed clinical trials back on track

...the pandemic today can be built into a long-term China strategy for tomorrow.” Lingshi Tan, dMed...
...CEO at dMed. Signed commentaries do not necessarily reflect the views of BioCentury. Lingshi Tan, dMed Global dMed...
BioCentury | Feb 8, 2020
Product Development

As coronavirus disrupts MNC operations in China, companies look to digital solutions

...stopped in most hospitals,” said Yan Yi, head of clinical and commercial operations at CRO dMed...
...such as prioritizing the most urgent trials to address current disruptions. Digital solutions Zhang and dMed's...
...are in better shape to manage the current situation.” George Baeder, dMed According to Baeder, dMed...
BioCentury | Nov 18, 2019
Finance

How Quan intends to build cross-border start-ups with second fund

...fund invested in 11 companies and has exited two of them, Armo BioSciences Inc and dMed...
...and Co. (NYSE:LLY) acquired Armo last year for $1.6 billion last year. Quan invested in dMed...
BioCentury | Nov 18, 2019
Finance

How Quan intends to build cross-border start-ups with its second fund

...fund invested in 11 companies and has exited two of them, Armo BioSciences Inc and dMed...
...and Co. (NYSE:LLY) acquired Armo last year for $1.6 billion last year. Quan invested in dMed...
BioCentury | Oct 17, 2019
Financial News

Oct. 16 Financial Quick Takes: Hong Kong IPO could value Ascentage at $876M; plus Principia, Rhythm, ProQR, dMed, Ionova and Amarna

...a 12% discount from Tuesday’s close of $6.22. Vivo leads dMed's $50M series B Shanghai-based dMed...
...will allow the CRO to expand its clinical operations and information technology infrastructure. In June, dMed...
...appointed Thomas Eldered as chair. Hongjiang Li, Staff Writer and Val Kennedy, Associate Editor Ascentage Pharma Group International dMed...
BioCentury | Sep 26, 2019
Tools & Techniques

Biotechs propose solutions to impending shortage of AI talent

...looking to fill a different talent gap: the need for clinical trial specialists in China. dMed...
Items per page:
1 - 10 of 32